Services
Pharmacogenetics
Cytochrome P450 assay services
The Cytochrome P450 family of enzymes is
responsible for the metabolism of many widely-prescribed and over
the counter drugs. LGC’s assay service provides routine
genotyping for well-understood drug metabolising genes such as:
CYP2D6, CYP2C9 and CYP2C19.
What we do
For subject selection in clinical trial
populations or for determining metabolic activity in patients
taking marketed drugs, LGC Genomics provides a five-day turnaround
time from sample receipt to prediction of phenotype.
CYP2D6 licensing
In the FDA March 2005 Guidance for Industry
Pharmacogenomic Data Submissions, CYP2D6 is particularly noted as
an example of a known valid biomarker. This guidance indicates the
desirability of the inclusion of test data for CYP2D6 for a variety
of drug development submissions.
The most common polymorphisms found in the
CYP2D6 gene are the subject of a patent portfolio in the name of
Cancer Research UK and exclusively licensed to the University of
Dundee. LGC has an exclusive agreement with the University of
Dundee to commercialise this technology and any organisation
interested in offering CYP2D6 products or services should enquire
for options and terms to access these granted patents for key
polymorphisms with the CYP2D6 gene.
For contact details click
here.